Immunogenicity and tolerability of booster doses of AERAS 402 after priming with BCG.

Next Previous
Trial Profile

Immunogenicity and tolerability of booster doses of AERAS 402 after priming with BCG.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2010

At a glance

  • Drugs BCG vaccine; Tuberculosis vaccine
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Crucell

    • Most Recent Events

    • 14 Apr 2010 Status changed from not yet recruiting to recruiting, based on results in a Crucell media release.
    • 28 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top